Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 11

760P - Efficacy and safety of nimotuzumab plus radiotherapy for elderly patients with locally advanced cervical squamous cell carcinoma

Date

21 Oct 2023

Session

Poster session 11

Topics

Tumour Site

Cervical Cancer

Presenters

Ang Qu

Citation

Annals of Oncology (2023) 34 (suppl_2): S507-S542. 10.1016/S0923-7534(23)01937-3

Authors

A. Qu1, J. Wang1, Y. Zhuo2, Z. Liu3, H. Zhu4, L. Wei5, X. Sun6, Y. Gao7, H. Cheng8, F. Zhao9, Y. Song10, Q.L. Wen11, X. Zhou12, P. Wang13, J. Yang14, L. Zou15, X. Yuan16, D. Wu17, J. He18, Y. Zhang19

Author affiliations

  • 1 Department Of Radiation Oncology, Peking University Third Hospital, 100191 - Beijing/CN
  • 2 Department Of Radiation Oncology, Zhangzhou Municipal Hospital of Fujian Province, 363000 - Zhangzhou/CN
  • 3 Department Of Radiation Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, 710061 - Xi'an/CN
  • 4 Department Of Oncology, Xiangya Hospital of Central South University, 410008 - Changsha/CN
  • 5 Department Of Radiotherapy, Xijing Hospital, 710032 - Xi’an/CN
  • 6 Department Of Radiotherapy, The Affiliated Hospital of Inner Mongolia Medical University, 010050 - Hohhot/CN
  • 7 Gynecological Radiotherapy Ward, Liaoning Cancer Hospital & Institute, 110042 - Shenyang/CN
  • 8 The Seventh Ward Of Gynecological Oncology Department, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, 450003 - Zhengzhou/CN
  • 9 Department Of Radiotherapy, Gansu Provincial Cancer Hospital, 730050 - Lanzhou/CN
  • 10 Department Of Radiotherapy, Yantai Yuhunagding Hospital, 264099 - Yantai/CN
  • 11 Department Of Oncology, The Affiliated Hospital of Southwest Medical University, 646099 - Luzhou/CN
  • 12 Cancer Radiotherapy Center, Jiamusi Tumor Tuberculosis Hospital, 154000 - Jiamusi/CN
  • 13 Department Of Radiotherapy And Chemotherapy, Tangshan People's Hospital, 639001 - Tangshan/CN
  • 14 Department Of Radiotherapy, Sichuan Cancer Hospital, 610042 - Chengdu/CN
  • 15 Department Of Radiation Oncology, The Second Hospital of Dalian Medical University, 116000 - Dalian/CN
  • 16 Radiation Oncology, Cangzhou Hospital of Integrated TCM-WM·Hebei, 061000 - Cangzhou/CN
  • 17 Gynecology Department, Qinghai provincial people's hospital, 810000 - Xining/CN
  • 18 Department Of Radiotherapy, General Hospital of Ningxia Medical University, 750004 - Yinchuan/CN
  • 19 Gynecological Radiotherapy Ward, Harbin Medical University Cancer Hospital, 150000 - Harbin/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 760P

Background

Although concurrent chemoradiotherapy is the standard treatment for locally advanced cervical cancer, elderly patients are often intolerable to chemotherapy. It’s urgent to explore a suitable regimen for these population. Cervical squamous cell carcinoma (CSCC) is characterized by the high expression of epidermal growth factor receptor (EGFR). Nimotuzumab is a recombinant humanized anti-EGFR monoclonal antibody with good safety. This study aimed to investigate the efficacy and safety of nimotuzumab plus radiotherapy in the treatment of elderly patients with locally advanced cervical squamous cell carcinoma (LACSCC).

Methods

It’s a prospective, multicenter, and single-arm trial. Key inclusion criteria included aged ≥ 65 years, histologically diagnosed CSCC with clinical stage IB3-ⅣA, ECOG 0-2, and refusing chemotherapy. Patients received nimotuzumab with 200mg/w for 6 weeks, underwent radiotherapy, including intensity-modulated radiotherapy (IMRT), volumetric intensity modulated arc therapy (VMAT) (45-50.4Gy, 1.8-2.0Gy/f, 25-28f), and brachytherapy (HR-CTV D90, 80-85Gy). Brachytherapy combined with external beam radiotherapy was completed within 8 weeks. The current endpoints include objective response rate (ORR), complete response rate (CRR), disease control rate (DCR), and safety.

Results

This trial enrolled 122 elderly LACSCC patients from Nov 2021 to Jan 2023. The median age was 72.5 years old (range from 65 to 92) with clinical stage IB3-ⅣA. The addition of nimotuzumab to radiotherapy exhibited a significant improvement in short-term efficacy with ORR of 87.70% (107/122), CRR of 42.62% (52/122), and DCR of 92.62% (113/122). The partial response was 45.08% (55/122), progressive disease was 2.50% (3/122), and stable disease was 4.92% (6/122). So far, no drug-related adverse events have occurred.

Conclusions

Nimotuzumab plus radiotherapy provided significant improvements in ORR, CRR, and DCR in elderly patients with LACSCC. No drug-related adverse events were observed. Our results demonstrate that nimotuzumab combined with radiotherapy may provide a choice for this population with better efficacy and tolerance.

Clinical trial identification

NCT04976478.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.